clinical trial · NCT03602508
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
Astellas Pharma Singapore Pte. Ltd.·—·completed·n = 5,589
Overactive Bladder (OAB)mirabegronsolifenacindarifenacinimidafenacintolterodineoxybutynintrospiumfesoterodine
brief summary
The purpose of this study is to descriptively evaluate the persistence among adults treated with mirabegron or antimuscarinics in Australia, South Korea and Taiwan. This study will also assess the persistence to the overall Overactive bladder (OAB) treatments of a patient, regardless of treatment discontinuation or switch to other OAB medications.
started
Jul 20, 2018
primary completion
Sep 13, 2019
completion
Sep 13, 2019
last updated
Oct 16, 2024
detailed description
This study is entirely descriptive using secondary medical claim and pharmacy prescription data. No formal comparisons between users of mirabegron and antimuscarinic will be made. Furthermore, no a priori hypothesis testing is intended.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol